Vetoquinol SA (EPA:VETO)

Market Cap	950.73M +6.6%
Revenue (ttm)	525.70M -2.5%
Net Income	57.30M -2.4%
EPS	n/a
Shares Out	11.80M
PE Ratio	16.59
Forward PE	15.36
Dividend	0.93 (1.15%)
Ex-Dividend Date	Jun 4, 2025

Volume	2,418
Average Volume	2,327
Open	80.60
Previous Close	80.60
Day's Range	79.10 - 81.50
52-Week Range	68.70 - 91.50
Beta	0.95
RSI	51.44
Earnings Date	Mar 27, 2026

About Vetoquinol

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1933
• Employees: 2,497
• Stock Exchange: Euronext Paris
• Ticker Symbol: VETO

Financial Performance

In 2025, Vetoquinol's revenue was 525.70 million, a decrease of -2.50% compared to the previous year's 539.20 million. Earnings were 57.30 million, a decrease of -2.36%.